Skip to main content
Surasak Phuphanich, MD, Neurology, Los Angeles, CA

SurasakPhuphanichMDFAAN

Neurology Los Angeles, CA

Neurooncology

Senior Neurologist/Neuro-Oncologist Consultant

Dr. Phuphanich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Phuphanich's full profile

Already have an account?

  • Office

    11949 Jefferson Blvd. Ste 102
    Los Angeles, CA 90230
    Phone+1 424-257-8869
    Fax+1 310-602-6446

Summary

  • My main clinical and research interests are drug delivery with nano-particle through blood brain barrier (BBB) and drug discovery with focus on promising new targeted therapeutic agents i.e. M-Tor inhibitor, EGFR-TKI, VEGFR, Monoclonal antibody, Gene therapy and Immunotherapy with Vaccine and Stem cell for different specific cancer cell targets including correlation with proteinomic, genomic profile in order to avoid major side effects and maintain high quality of life in this group of patients with the ultimate goal of offering personalized Neuro-Oncology medicine for every patient with brain cancer. I have more than 25 years of experience in this field for translational clinical research.

Education & Training

  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1978 - 1979
  • Ascension Illinois/Saint Francis
    Ascension Illinois/Saint FrancisInternship, Internal Medicine, 1977 - 1978
  • Mahidol University Faculty of Medicine
    Mahidol University Faculty of MedicineClass of 1975
  • Mahidol University
    Mahidol UniversityB.S., Faculty of Science, 1973

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2006 - 2026
  • OR State Medical License
    OR State Medical License 2022 - 2025
  • AZ State Medical License
    AZ State Medical License 2016 - 2021
  • FL State Medical License
    FL State Medical License 1983 - 2009
  • GA State Medical License
    GA State Medical License 2003 - 2009
  • IL State Medical License
    IL State Medical License 1978 - 1984
  • American Board of Psychiatry and Neurology Neurology
  • United States Department of Justice Drug Enforcement Administration (DEA)

Awards, Honors, & Recognition

  • LA’s Top Doctors, Los Angeles Magazine Los Angeles Magazine, 2021
  • Top Doctors:LA Area Castle Connolly, 2013, 2016
  • Top's American Doctors for Cancer Castle Connelly Medical Ltd, 2006-2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma  
    David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
  • A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation ...  
    Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli VK, LoghinM, Paleologos N, Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont I..., J Neurooncol, 1/1/2015
  • Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma  
    Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ..., Neurology, 1/1/2015
  • Join now to see all

Abstracts/Posters

  • Nanoconjugates for inhibition of laminin 411-integrin B1 Dll4 Notch1 pathway to treat glioblastoma multiforme
    Gangalum PR, Ljubimov AV, Chesnokova A, Konda B, Ding H, Portilla-Arias J, Mamelak A, Bannykh S, Rudnick J, Hu J, Black KL, Ljubimova JY, Cancer Res, 1/1/2014
  • A randomized, double blind, controlled phase II trial of dendritic cell (DC) vaccination with ICT107 in newly diagnosed glioblastoma (GBM) patients
    Wen P, Reardon D, Armstrong T, Aiken R, Landolfi J, Curry W, Zhu J, Glantz M, Peerboom D, Markert J, Grewal J, LaRocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G..., American Society of Clinical Oncology, Chicago, IL, 1/1/2014
  • BTTC08 01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT prom...
    Raizer J, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Puduvalli V, Loghin M, Paleologos N., Yung A, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-L..., American Society of Clinical Oncology, Chicago, IL, 1/3/2012
  • Join now to see all

Lectures

  • Advances in Neuro-Oncology 2015: Biomarker, Liquid Biopsy Immuno-Oncology, NovoTTF 
    Ramathibodi Hospital, Mahidol University, Bangkok, Thailand - 1/16/2015
  • Targeted Therapy for Brain Cancer: Early Detection and New Biomarker 
    Mahachai Hospital Group, Samutsakhon, Thailand - 1/15/2015
  • Immunotherapy for Brain cancer: Vaccine, ICT 107 Anti PD1 PD L1 Antibody 
    Houston Methodist Hospital, Houston, TX - 1/24/2014
  • Join now to see all

Authored Content

  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020

Press Mentions

  • Update: 50 Percent of Patients in New Brain Cancer Study Alive After Five Years
    Update: 50 Percent of Patients in New Brain Cancer Study Alive After Five YearsNovember 24th, 2013
  • Vaccine Targets Malignant Brain Cancer Antigens, Significantly Lengthens Survival
    Vaccine Targets Malignant Brain Cancer Antigens, Significantly Lengthens SurvivalAugust 15th, 2012
  • Vaccine Study Supports Immune Targeting of Brain Tumors
    Vaccine Study Supports Immune Targeting of Brain TumorsJune 17th, 2011

Professional Memberships